Expert Weighs In On The Future of PARP Inhibitors

Wednesday, October 09, 2019

Patients with advanced ovarian cancer have a higher likelihood of recurrence: over 80% recur after their first-line platinum treatment, according to Bhavana Pothuri, MD, gynecologic oncologist at the NYU Langone Medical Center Perlmutter Cancer Center. One of the reasons for this high rate of recurrence is treatments in the frontline not being effective right away, but that could now change with the addition of PARP inhibitors like niraparib (Zejula).  

At the European Society of Medical Oncology 2019 Congress, OncLive®, a sister publication of Oncology Nursing News® , had the chance to interview Pothuri on the implications of the PRIMA study, presented at the conference. She highlighted the effectiveness of niraparib and where the future of PARP inhibitors could go from here.

We still need to think about all the data carefully, determine whether HRD testing is indicated in the upfront setting, whether patients who have BRCA-positive tumors or HRD-positive tumors should be prioritized to receive the PARP inhibitor in the frontline setting and perhaps thinking about different strategies in terms of utilizing maintenance in the biomarker-negative group.  

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.